全球新冠肺炎治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計新冠肺炎治療藥物的市場規模將從 2025 年的 363.9 億美元成長到 2034 年的 1,590.9 億美元，2026 年至 2034 年的複合年成長率為 17.81%。

隨著全球新冠疫情的蔓延，醫療系統為因應感染疾病期間對有效治療方法的需求，全球新冠市場迅速擴張。製藥公司和研究機構開發了多種抗病毒藥物和輔助療法，旨在減輕疾病嚴重程度並改善患者預後。這些藥物成為控制感染疾病和緩解併發症的重要工具。

多種因素促成了這一市場的成長。全球對醫藥研發投入的增加加速了藥物開發和臨床試驗。各國政府和醫療機構與製藥公司合作，確保治療藥物的快速生產和分發。生物技術的進步也推動了創新療法的開發。

隨著醫療系統持續監測和管理呼吸道病毒性疾病，新冠肺炎治療市場預計仍將保持重要地位。持續進行的抗病毒療法和治療策略改進研究將支撐未來的市場成長。此外，從應對新冠疫情中汲取的經驗教訓將有助於加強全球應對新興感染疾病的準備。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球新冠肺炎治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 皮質類固醇
• 抗病毒藥物
• 單株抗體
• 激酶抑制劑
• 其他

第5章：全球新冠肺炎治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 靜脈注射

第6章：全球新冠肺炎治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球新冠肺炎治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Pfizer Inc
  • Johnson & Johnson
  • Merck & Co. Inc
  • GlaxoSmithKline Plc
  • AstraZeneca Plc
  • Moderna Inc
  • Novavax Inc
  • Serum Institute Of India Pvt. Ltd
  • Bharat Biotech International Limited
  • Cadila Healthcare Limited（Zydus Lifesciences Ltd.）
  • Dr. Reddy'S Laboratories Ltd
  • Glenmark Pharmaceuticals Limited
  • CanSino Biologics Inc
  • Sinovac Biotech Ltd

The Novel Coronavirus Drugs Market size is expected to reach USD 159.09 Billion in 2034 from USD 36.39 Billion (2025) growing at a CAGR of 17.81% during 2026-2034.

The global novel coronavirus drugs market expanded rapidly as healthcare systems responded to the need for effective treatments during the coronavirus pandemic. Pharmaceutical companies and research institutions developed various antiviral medications and supportive therapies aimed at reducing the severity of the disease and improving patient outcomes. These drugs became essential tools in managing infections and reducing complications.

Several factors contributed to the growth of this market. Increased global investment in pharmaceutical research accelerated drug development and clinical trials. Governments and healthcare organizations collaborated with pharmaceutical companies to ensure rapid production and distribution of treatments. Advances in biotechnology also enabled the development of innovative therapeutic approaches.

Looking forward, the novel coronavirus drugs market is expected to remain important as healthcare systems continue to monitor and manage respiratory viral diseases. Ongoing research into antiviral therapies and improved treatment strategies will support future market growth. Lessons learned from pandemic response efforts will also strengthen global preparedness for emerging infectious diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Corticosteroids
• Anti-viral
• Monoclonal Antibodies
• Kinase Inhibitors
• Others

By Route of Administration

• Oral
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Pfizer Inc, Johnson Johnson, Merck Co Inc, GlaxoSmithKline plc, AstraZeneca plc, Moderna Inc, Novavax Inc, Serum Institute of India Pvt Ltd, Bharat Biotech International Limited, Cadila Healthcare Limited Zydus Lifesciences Ltd, Dr Reddys Laboratories Ltd, Glenmark Pharmaceuticals Limited, CanSino Biologics Inc, Sinovac Biotech Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL NOVEL CORONAVIRUS DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Anti-viral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Kinase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NOVEL CORONAVIRUS DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NOVEL CORONAVIRUS DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NOVEL CORONAVIRUS DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL NOVEL CORONAVIRUS DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Johnson & Johnson
  • 9.2.3 Merck & Co. Inc
  • 9.2.4 GlaxoSmithKline Plc
  • 9.2.5 AstraZeneca Plc
  • 9.2.6 Moderna Inc
  • 9.2.7 Novavax Inc
  • 9.2.8 Serum Institute Of India Pvt. Ltd
  • 9.2.9 Bharat Biotech International Limited
  • 9.2.10 Cadila Healthcare Limited (Zydus Lifesciences Ltd.)
  • 9.2.11 Dr. Reddy'S Laboratories Ltd
  • 9.2.12 Glenmark Pharmaceuticals Limited
  • 9.2.13 CanSino Biologics Inc
  • 9.2.14 Sinovac Biotech Ltd